Cargando…

The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease worldwide, mirroring the epidemics of obesity and metabolic syndrome. As there are still no licensed medications for treating the disease, there is an ongoing effort to elucidate the pathophysiology and to disc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forlano, Roberta, Mullish, Benjamin H., Roberts, Lauren A., Thursz, Mark R., Manousou, Pinelopi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775587/ https://www.ncbi.nlm.nih.gov/pubmed/35054847 http://dx.doi.org/10.3390/ijms23020662

Ejemplares similares

Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?
por: Forlano, Roberta, et al.
Publicado: (2021)

Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
por: Forlano, Roberta, et al.
Publicado: (2022)

Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Jambulingam, Nila, et al.
Publicado: (2023)

Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
por: Huang, Jian, et al.
Publicado: (2023)

Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non‐alcoholic fatty liver disease; the importance of an elevated mean platelet volume
por: Abeles, Robin D., et al.
Publicado: (2019)

Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts
por: Eng, Pei Chia, et al.
Publicado: (2023)

High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease
por: Forlano, Roberta, et al.
Publicado: (2020)

Screening for NAFLD—Current Knowledge and Challenges
por: Forlano, Roberta, et al.
Publicado: (2023)

Current and future pharmacological therapies for managing cirrhosis and its complications
por: Kockerling, David, et al.
Publicado: (2019)

The effects of dietary supplementation with inulin and inulin‐propionate ester on hepatic steatosis in adults with non‐alcoholic fatty liver disease
por: Chambers, Edward S., et al.
Publicado: (2018)

Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in non‐alcoholic fatty liver disease
por: Baumann, Anja, et al.
Publicado: (2022)

THU642 Progression To Cirrhosis And All-cause Mortality Are Increased In Postmenopausal Women With NAFLD
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2023)

In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19
por: Forlano, Roberta, et al.
Publicado: (2020)

Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats
por: Li, Donghao, et al.
Publicado: (2017)

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
por: Jung, Han Na, et al.
Publicado: (2023)

Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine
por: Brandt, Annette, et al.
Publicado: (2019)

Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function
por: Yu, Shenglan, et al.
Publicado: (2022)

Translational Approaches with Antioxidant Phytochemicals against Alcohol-Mediated Oxidative Stress, Gut Dysbiosis, Intestinal Barrier Dysfunction, and Fatty Liver Disease
por: Ballway, Jacob W., et al.
Publicado: (2021)

Gut Dysfunction and Non-alcoholic Fatty Liver Disease
por: Grabherr, Felix, et al.
Publicado: (2019)

GRHL2 induces liver fibrosis and intestinal mucosal barrier dysfunction in non‐alcoholic fatty liver disease via microRNA‐200 and the MAPK pathway
por: Wang, Ying, et al.
Publicado: (2020)

Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis
por: Virk, Ghazala S, et al.
Publicado: (2023)

Low–Normal Thyroid Function Is Not Associated with Either Non-Alcoholic Fatty Liver Disease or with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Zuarth-Vázquez, Julia, et al.
Publicado: (2023)

Alcohol and Metabolic-associated Fatty Liver Disease
por: Sun, Fu-Rong, et al.
Publicado: (2021)

Intestinal Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease
por: Liu, Lu, et al.
Publicado: (2023)

Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder
por: Kim, Jin Un, et al.
Publicado: (2020)

Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors’ Combination
por: Quesada-Vázquez, Sergio, et al.
Publicado: (2022)

Metabolic dysfunction-associated fatty liver disease reflects a significantly higher risk of hypertension than non-alcoholic fatty liver disease
por: Uehara, Tatsuki, et al.
Publicado: (2023)

Causes of erectile dysfunction in non-alcoholic fatty liver disease
por: Tarik Kani, Haluk, et al.
Publicado: (2021)

The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases
por: Ghani, Rohma, et al.
Publicado: (2022)

Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?
por: Devi, Jalpa, et al.
Publicado: (2022)

Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non-alcoholic fatty liver disease
por: Zeng, Jialiu, et al.
Publicado: (2023)

Experimental models of metabolic and alcoholic fatty liver disease
por: Buyco, Delfin Gerard, et al.
Publicado: (2021)

Metabolic drivers of non-alcoholic fatty liver disease
por: Bence, Kendra K., et al.
Publicado: (2020)

The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases
por: An, Lingxuan, et al.
Publicado: (2021)

Increased Nitroxidative Stress Promotes Mitochondrial Dysfunction in Alcoholic and Nonalcoholic Fatty Liver Disease
por: Song, Byoung-Joon, et al.
Publicado: (2013)

Fenretinide Improves Intestinal Barrier Function and Mitigates Alcohol Liver Disease
por: Tang, Xiao-Han, et al.
Publicado: (2021)

Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention
por: Skinner, Charlotte, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease may be associated with endothelial dysfunction
por: Balta, Sevket, et al.
Publicado: (2014)

Endothelial dysfunction and carotid atherosclerosis in non-alcoholic fatty liver disease
por: Dogru, Teoman, et al.
Publicado: (2014)

“Non alcoholic fatty liver disease and eNOS dysfunction in humans”
por: Persico, Marcello, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_50rnm1kjkv3n68d61lc9hfp7q7